Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Avivit Cahn

Showing results (91-100 of 96) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 96 results.
The New England Journal of Medicine|November 13, 2018
Dapagliflozin and Cardiovascular Outcomes in Type 2 DiabetesStephen D Wiviott, Itamar Raz, Marc P Bonaca, et al.
Diabetes Care|July 8, 2021
The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58Ofri Mosenzon, Stephen D Wiviott, Hiddo J L Heerspink, et al.
Diabetes Care|August 23, 2022
Dapagliflozin and Prevention of Kidney Disease Among Patients With Type 2 Diabetes: Post Hoc Analyses From the DECLARE-TIMI 58 TrialOfri Mosenzon, Itamar Raz, Stephen D Wiviott, et al.
The Lancet. Diabetes & Endocrinology|June 15, 2019
Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trialOfri Mosenzon, Stephen D Wiviott, Avivit Cahn, et al.
Circulation|March 19, 2019
Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes MellitusEri T Kato, Michael G Silverman, Ofri Mosenzon, et al.
Journal of Diabetes and Its Complications|April 30, 2025
Obesity and its management in primary care settingMahmoud Ibrahim, Ebtesam M Ba-Essa, Jessica A Alvarez, et al.
Pageof 10

Showing results (91-100 of 96) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 96 results.
The New England Journal of Medicine|November 13, 2018
Dapagliflozin and Cardiovascular Outcomes in Type 2 DiabetesStephen D Wiviott, Itamar Raz, Marc P Bonaca, et al.
Diabetes Care|July 8, 2021
The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58Ofri Mosenzon, Stephen D Wiviott, Hiddo J L Heerspink, et al.
Diabetes Care|August 23, 2022
Dapagliflozin and Prevention of Kidney Disease Among Patients With Type 2 Diabetes: Post Hoc Analyses From the DECLARE-TIMI 58 TrialOfri Mosenzon, Itamar Raz, Stephen D Wiviott, et al.
The Lancet. Diabetes & Endocrinology|June 15, 2019
Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trialOfri Mosenzon, Stephen D Wiviott, Avivit Cahn, et al.
Circulation|March 19, 2019
Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes MellitusEri T Kato, Michael G Silverman, Ofri Mosenzon, et al.
Journal of Diabetes and Its Complications|April 30, 2025
Obesity and its management in primary care settingMahmoud Ibrahim, Ebtesam M Ba-Essa, Jessica A Alvarez, et al.
Pageof 10